Fig. 4

HH2853 pharmacokinetics and pharmacodynamics. (A) Plasma concentration of HH2853 over time across various dose cohorts (300 mg, 400 mg, and 600 mg). (B) Percentage change from baseline of H3K27me3 in peripheral monocytes in PTCL patients. Observed data are represented by median with interquartile range